• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Infect Dis . Relative effectiveness of the high-dose versus standard-dose influenza vaccines for the prevention of laboratory-confirmed influe

tetano

Editor, Senior Moderator
Int J Infect Dis


. 2025 Oct 1:108100.
doi: 10.1016/j.ijid.2025.108100. Online ahead of print. Relative effectiveness of the high-dose versus standard-dose influenza vaccines for the prevention of laboratory-confirmed influenza among Italian older adults during three recent seasons

Alexander Domnich[SUP] 1 [/SUP], Andrea Orsi[SUP] 2 [/SUP], Alessio Signori[SUP] 3 [/SUP], Donatella Panatto[SUP] 4 [/SUP], Giancarlo Icardi[SUP] 2 [/SUP]



Affiliations
Abstract

Objectives: This study aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose (SD-IIV) inactivated influenza vaccines against laboratory-confirmed influenza among older adults in Liguria (Italy), Europe's oldest region.
Methods: An integrated analysis of inpatient and outpatient data collected between the 2022/2023 and 2024/2025 seasons was performed using a test-negative approach. Adults aged ≥60 years vaccinated with either HD-IIV or SD-IIV and molecularly tested for influenza were eligible. For the base-case, rVE was estimated through conditional logistic regression. Alternative approaches, including the inverse probability of treatment weighting (IPTW), were used in sensitivity analyses.
Results: Among 1,238 vaccinated older adults included in the analysis, influenza positivity prevalence was lower (P=0.022) in HD-IIV (6.6%; 46/693) than SD-IIV (10.3%; 56/545) recipients. rVE of HD-IIV versus SD-IIV was 29% (95% CI: -22%, 59%) among subjects aged ≥60 years. Among adults aged ≥80 years, for whom HD-IIV was preferentially recommended, HD-IIV was more effective than SD-IIV by 54% (95% CI: 10%, 76%). IPTW-derived estimates were similar in both ≥60-year-olds (32%; 95% CI: -20%, 61%) and ≥80-year-olds (53%; 95% CI: 7%, 77%).
Conclusions: Italian older adults, especially the oldest old, vaccinated with HD-IIV experienced fewer influenza episodes than those immunized with SD-IIV.

Keywords: High-dose influenza vaccine; Influenza; Older adults; Vaccination; Vaccine effectiveness.

 
Back
Top Bottom